Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Narrative (Details)

v3.23.1
Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 12 Months Ended
Oct. 22, 2019
$ / shares
shares
Mar. 31, 2022
shares
Dec. 31, 2022
USD ($)
segment
shares
Dec. 31, 2021
USD ($)
shares
Financing Receivable, Impaired [Line Items]        
Tangible asset impairment charges | $     $ 0 $ 0
Asset impairment charges | $     $ 0 $ 0
Common stock, shares issued (in shares) 1   49,445,174 48,627,739
Research and development expense | $     $ 10,409,000 $ 6,281,000
Advertising expense | $     $ 2,046,000 $ 1,887,000
Percentage of largest benefit greater than likelihood of resolution for tax benefit measurement     50.00%  
Effective income tax reconciliation rate     (0.17%) (1.94%)
Weighted average shares included in computation of earning per share   4,515,739 3,885,059  
Number of operating segments | segment     1  
Minimum        
Financing Receivable, Impaired [Line Items]        
Intangible asset useful life     2 years  
Lease terms     4 years  
Maximum        
Financing Receivable, Impaired [Line Items]        
Intangible asset useful life     10 years  
Lease terms     10 years  
IPO        
Financing Receivable, Impaired [Line Items]        
Stock issued during period new shares issued (in shares) 13,800,000      
Shares issued (in shares) 1      
Purchase price per share (in dollars per share) | $ / shares $ 10.00      
IPO | Private Warrants        
Financing Receivable, Impaired [Line Items]        
Warrants issued (in shares) 1      
Private Placement | Private Warrants        
Financing Receivable, Impaired [Line Items]        
Stock issued during period new shares issued (in shares) 4,110,000      
Exercise price of warrants or rights (dollars per share) | $ / shares $ 1.00      
Conversion of promissory note, warrants issued (in shares) 500,000